Abstract:
Over the last decade, our research provides strong evidence that the drivers of minimal residual disease (MRD) survival are different from those that drive bulk ovarian cancer. Therefore, eliminating minimal residual disease at the end of traditional treatment requires rationalised therapeutics that specifically target MRD drivers. In this talk I will discuss our recent work in characterising MRD in ovarian cancer and our ongoing work to develop therapeutics to eliminate it.